Your session is about to expire
Ditropan vs Vesicare
Introduction
For patients suffering from overactive bladder (OAB) or other urinary conditions, certain drugs that modify the activity of nerves controlling the bladder can help manage symptoms. Ditropan and Vesicare are two such medications commonly prescribed for OAB. Both affect different receptors in the body but have similar effects in reducing urinary frequency, urgency, and incontinence. Ditropan is an anticholinergic medication acting on muscarinic receptors to reduce muscle spasms in the bladder. On the other hand, Vesicare is categorized as a competitive muscarinic receptor antagonist, primarily affecting smooth muscle contraction within the urinary tract.
Ditropan vs Vesicare Side By Side
| Attribute | Ditropan | Vesicare |
|---|---|---|
| Brand Name | Ditropan | Vesicare |
| Contraindications | Untreated narrow-angle glaucoma, myasthenia gravis, severe liver disease, severe kidney disease, taking or have taken anticholinergic drugs. | Untreated narrow-angle glaucoma, myasthenia gravis, severe liver disease, severe kidney disease, taking or have taken anticholinergic drugs. |
| Cost | For brand name: around $250 for 60 tablets of 5 mg. For generic (oxybutynin chloride): as low as $0.50 to about $1.40 per day. | For brand name: about $320 for 30 capsules of 10 mg. For generic (solifenacin succinate): between roughly $2.65 and just under $3 per day. |
| Generic Name | Oxybutynin | Solifenacin |
| Most Serious Side Effect | Severe stomach pain or constipation, little to no urination, painful or difficult urination, signs of an allergic reaction. | Severe stomach pain with constipation, dehydration symptoms, hallucinations, confusion or changes in behavior. |
| Severe Drug Interactions | Anticholinergic drugs. | Anticholinergic drugs. |
| Typical Dose | 5 mg two to three times a day, effective dose range between 10-30 mg per day. | 5 mg once daily, can be increased to 10 mg per day if needed and tolerated. |
What is Ditropan?
Oxybutynin (the generic name for Ditropan) is a long-established anticholinergic medication first approved by the FDA in 1975. It's primarily used to treat overactive bladder, a condition characterized by frequent urination, urinary urgency, and for some people, urinary incontinence. Oxybutynin works by relaxing the bladder muscles to prevent urgent, frequent or uncontrolled urination. However, because it blocks acetylcholine activity not just in the bladder but throughout the body as well; it can potentially cause side effects like dry mouth and constipation.
Solifenacin (the generic name for Vesicare), on other hand was approved much later in 2004. Like Oxybutynin, Solifenacin also treats symptoms of an overactive bladder by inhibiting certain receptors in the bladder muscle helping reduce spasms that can cause urgency and frequency. What sets it apart though is its selective targeting of muscarinic receptors which results in fewer drying side effects than those seen with nonselective anticholinergics like Oxybutynin.
What conditions is Ditropan approved to treat?
Ditropan is approved for the treatment of various bladder and urinary conditions:
- Overactive bladder, which causes a frequent urge to urinate
- Urinary incontinence, where there's a loss of bladder control
- Neurogenic bladder disorders (a condition affecting nerve signals to the bladder), often resulting from spinal cord injuries or multiple sclerosis.
How does Ditropan help with these illnesses?
Ditropan aids in managing overactive bladder symptoms by impeding the action of acetylcholine on smooth muscle cells within the bladder. It does this by blocking muscarinic receptors, which prevents the contraction of these muscles and allows for increased bladder capacity. Acetylcholine is a neurotransmitter, a chemical that sends signals throughout your body, playing key roles in functions involving heart rate regulation and memory processing among others. In cases of overactive bladder, there are higher levels of acetylcholine leading to frequent contractions hence causing urgency or urinary incontinence. By reducing acetylcholine's impact, Ditropan can limit disruptive effects associated with an overactive bladder helping patients manage their condition and improve their quality of life.
What is Vesicare?
Vesicare, also known by its generic name solifenacin, is a type of medication called an antimuscarinic. It works to treat overactive bladder (a condition characterized by frequent urination and urgency) by relaxing the muscles in the bladder, thus reducing spasms that can cause these symptoms. Vesicare was first approved for use by the FDA in 2004.
As an antimuscarinic, Vesicare reduces the effects of acetylcholine on muscarinic receptors to suppress involuntary muscle contractions. Unlike Ditropan (oxybutynin), which has similar effects but may cause more side-effects such as dry mouth and constipation due to its systemic action, Vesicare specifically targets receptors in the urinary tract making it less likely to produce these side effects. Its selective action can make it a better choice for patients who have not responded well or experienced intolerable side-effects with other medications like Ditropan.
What conditions is Vesicare approved to treat?
Vesicare, also known as solifenacin, is approved for managing specific symptoms of an overactive bladder including:
- Urgency and frequency in urination
- Urge urinary incontinence (an immediate need to urinate leading to accidental leakage)
How does Vesicare help with these illnesses?
Acetylcholine is a neurotransmitter involved in many functions, including muscle movement and the regulation of the heart rate. Inappropriate amounts or action of acetylcholine can lead to conditions such as overactive bladder. Vesicare works by blocking the action of acetylcholine on specific receptors (muscarinic receptors) present in the smooth muscle tissue lining the bladder, thereby reducing contractions and alleviating symptoms like frequent urination or urgency. Its focused effect on muscarinic receptors differentiates it from drugs like Ditropan that have more generalized anticholinergic effects and may cause side effects such as dry mouth or constipation. Hence, Vesicare might be prescribed when patients do not respond well to medications with broader anticholinergic activity, or it could be combined with them for enhanced effectiveness.
How effective are both Ditropan and Vesicare?
Both oxybutynin (Ditropan) and solifenacin (Vesicare) are effective medications for the management of overactive bladder, having proven their efficacy in numerous clinical trials. The FDA approved oxybutynin in 1975 and solifenacin almost 30 years later, in 2004. They act on different types of muscarinic receptors, which may lead to different side effect profiles.
A head-to-head comparison between oxybutynin and solifenacin was carried out during a randomized controlled trial in 2012; both drugs showed similar effectiveness at controlling urinary frequency, urgency, nocturia and urge-related leakage episodes. However, it's worth noting that patients taking oxybutynin reported slightly more dry mouth incidents compared with those using solifenacin.
In a comprehensive review conducted in 2019 that included data from multiple studies comparing antimuscarinic agents used for treating overactive bladder symptoms demonstrated that both drugs were highly efficient starting from the first week of treatment. This same study highlighted fewer withdrawal rates due to adverse events with Vesicare when compared to Ditropan.
Another meta-analysis published in 2020 suggested that while Ditropan is as effective as Vesicare at managing symptoms of an overactive bladder, it may be associated with more adverse effects such as constipation and memory problems. Therefore, Ditropan might be considered only after other treatments have failed or when there are specific reasons not to use first-line therapies like anticholinergics or beta-3 agonists.
Find Top Clinical Trials
Choose from over 30,000 active clinical trials.
At what dose is Ditropan typically prescribed?
Oral dosages of Ditropan typically start at 5 mg two to three times a day, with the effective dose range being between 10-30 mg per day. For Vesicare, the recommended starting dose is 5 mg once daily. If tolerated and if an increased therapeutic effect is needed, dosage may be increased to a maximum of 10 mg once daily for both adults and elderly patients. However, it's important to remember that any changes in medication or dosage should always be discussed with your healthcare provider first as individual responses can vary significantly. In all cases, the lowest effective dose that controls symptoms should be used.
At what dose is Vesicare typically prescribed?
Vesicare treatment typically begins at a dosage of 5 mg per day, taken orally once daily. If needed and tolerated, the dose can then be increased to 10 mg per day after a few weeks of observation for response to treatment and side effects. However, this increase should only be done under medical supervision as the higher dose may lead to more pronounced side effects. It's important to note that Vesicare tablets should be swallowed whole with water and can be taken with or without food.
What are the most common side effects for Ditropan?
Some common side effects of Ditropan (oxybutynin) include:
- Dry mouth
- Nervousness
- Dizziness, drowsiness or blurred vision
- Diarrhea, constipation or stomach pain
- Insomnia
- Headache
- Decreased sweating and increased body temperature (be careful during exercise)
- Mild skin rash
Compared to Vesicare (solifenacin), these medications share some similar side effects like dry mouth and constipation. However, Vesicare tends to cause fewer neurological symptoms such as nervousness and insomnia but may lead to other side effects including:
- Urinary tract infection
- Bladder infection
- Heat stroke due to decreased sweat production.
As with any medication, it is essential that you discuss potential side effects with your healthcare provider before starting a new treatment regimen.
Are there any potential serious side effects for Ditropan?
Ditropan, like any other medication, carries the potential for side effects. While many individuals tolerate it well, some may experience rare but serious side effects such as:
- Signs of an allergic reaction: hives; difficult breathing; swelling of your face or throat
- Severe stomach pain or constipation
- Little to no urination
- Painful or difficult urination,
- Dehydration symptoms - feeling very thirsty or hot, being unable to urinate, heavy sweating, or hot and dry skin.
On the other hand, Vesicare also has its own set of potential adverse reactions. Some are similar to Ditropan's but there are differences too:
- Allergic reactions including itching/swelling (especially of the face/tongue/throat), severe dizziness and trouble breathing.
- Low levels of sodium in the body which might lead to headache, confusion, slurred speech severely weak and unsteady feelings.
- Serious nervous system reaction showcasing rigid muscles with high fever leading up to tremors and uneven heartbeats.
If you encounter any such experiences while taking either Ditropan or Vesicare please ensure immediate medical assistance is sought after.
What are the most common side effects for Vesicare?
Common side effects of Vesicare include:
- Dry mouth and throat
- Blurred vision
- Nausea, stomach upset or pain, constipation
- Sleep disturbances such as insomnia
- Mild trembling or a feeling of anxiety
- Increased heart rate
- Mental confusion or restlessness
- Skin rash
- Infrequent urination due to its action on the bladder muscles
- Occasional headaches and dizziness
-Muscle weakness or joint discomfort
Please note that although these are potential side effects, not everyone experiences them. It's always important to discuss any concerns with your healthcare provider.
Are there any potential serious side effects for Vesicare?
Vesicare, like any medication, does occasionally cause side effects. For most people these are not serious but some warning signs to look out for include:
- Signs of an allergic reaction such as difficulty breathing; swelling of your face, lips, tongue or throat
- Blurred vision and increased sensitivity to light
- Painful urination or changes in the color and amount of urine
- Severe stomach pain with constipation
- Dehydration symptoms - feeling hot, unable to urinate, heavy sweating or hot and dry skin
- Hallucinations (seeing things that aren't there)
- Confusion or changes in behavior
If you experience any unusual symptoms after taking Vesicare it is recommended that you contact a doctor immediately.
Contraindications for Ditropan and Vesicare?
Both Ditropan and Vesicare, as with most other bladder control medications, may cause unwanted side effects in some people. If you notice an increase in difficulty urinating, constipation or blurry vision please seek immediate medical attention.
Neither Ditropan nor Vesicare can be taken if you are taking, or have been taking medicines that decrease the actions of acetylcholine (anticholinergic drugs). Always inform your physician about all medications you are currently on; anticholinergic drugs will require a period to clear from the system to prevent dangerous interactions with Ditropan and Vesicare.
Most importantly, individuals with untreated narrow-angle glaucoma should not take these medications. Also those suffering from myasthenia gravis (a type of muscle weakness), severe liver disease or kidney disease might need dosage adjustments for both Ditropan and Vesicare—be sure to discuss this thoroughly with your doctor.
How much do Ditropan and Vesicare cost?
For the brand name versions of these drugs:
- The price for 60 tablets of Ditropan (5 mg) averages around $250, which works out to approximately $4–8/day depending on your dose.
- Meanwhile, the average price for 30 capsules of Vesicare (10 mg) is about $320, thus costing approximately $11/day.
Consequently, if you are in the higher dosage range for Ditropan (i.e., 20 mg/day or higher), then brand-name Vesicare may be less expensive on a per-day treatment basis. However, cost should not be a primary consideration in determining which of these medications is right for you.
For generic versions — oxybutynin chloride (Ditropan's active ingredient) and solifenacin succinate (Vesicare's active ingredient), costs are significantly lower:
- Oxybutynin chloride comes in packs ranging from 30 to 90 tablets, with approximate costs as low as $0.50 up to about $1.40 per day based on dosages between 5mg and 15mg daily.
- Solifenacin succinate can be found in quantities from 30 to upwards of several hundred pills at a time; it typically costs between roughly $2.65 and just under $3 per day when taking standard doses between five and ten milligrams each day.
Popularity of Ditropan and Vesicare
Oxybutynin, available in generic form and under brand names such as Ditropan, was estimated to have been prescribed to about 3.2 million people in the US in 2020. Oxybutynin accounted for just over 10% of prescriptions for overactive bladder (OAB) medications in the US. This medication has been on a generally steady course since its introduction.
Solifenacin, including brand versions such as Vesicare, was prescribed to around 2 million people in the USA during that same year. In the US market, solifenacin accounts for around 7% of OAB prescriptions overall. The prevalence of solifenacin has also remained relatively stable over recent years.
Both these drugs are antimuscarinic agents that help manage symptoms of an overactive bladder like frequent or urgent urination; their effectiveness is comparable but side-effects profiles may differ slightly between individuals.
Conclusion
Both Ditropan (oxybutynin) and Vesicare (solifenacin) have reliable records of use in patients with overactive bladder symptoms, and are supported by numerous clinical studies demonstrating their effectiveness compared to placebo treatments. Occasionally, these drugs may be combined under careful consideration from a healthcare provider as they can also interact negatively. Due to their differing mechanisms of action - with Ditropan primarily inhibiting muscarinic receptors and Vesicare carefully balancing the inhibition of M3 receptors while sparing M2 - they're usually prescribed in different situations.
Ditropan is considered a first-line treatment option due to its longstanding history and lower cost, whereas Vesicare is typically used when patients don't respond well to initial treatment with oxybutynin or need to avoid certain side effects such as dry mouth or cognitive impairment.
Both medications are available in generic form providing significant savings for out-of-pocket paying patients. Both Ditropan and Vesicare might require an adjustment period; it could take several weeks before you notice improvement in your symptoms.
The side effect profile between the two drugs is similar, both being generally well-tolerated but with Vesicare slightly less likely than Ditropan to cause dry mouth or cognitive impairment. For both drugs, patients should closely monitor any adverse reactions especially when starting treatment, seeking immediate medial help if serious side effects occur.
Other Trials to Consider
Popular Categories
Popular Guides
Learn More About These Treatments
Refrences
- Cardozo, L., Heßdörfer, E., Milani, R., Arañó, P., Dewilde, L., Slack, M., … for the SUNRISE Study Group (see ). (2008, October 9). Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double‐blind, placebo‐controlled, rising‐dose trial. BJU International. Wiley.http://doi.org/10.1111/j.1464-410x.2008.07939.x
- Diokno, A. C., Appell, R. A., Sand, P. K., Dmochowski, R. R., Gburek, B. M., Klimberg, I. W., & Kell, S. H. (2003, June). Prospective, Randomized, Double-Blind Study of the Efficacy and Tolerability of the Extended-Release Formulations of Oxybutynin and Tolterodine for Overactive Bladder: Results of the OPERA Trial. Mayo Clinic Proceedings. Elsevier BV.http://doi.org/10.4065/78.6.687
- Van Arendonk, K. J., Knudson, M. J., Austin, J. C., & Cooper, C. S. (2006, October). Improved efficacy of extended release oxybutynin in children with persistent daytime urinary incontinence converted from regular oxybutynin. Urology. Elsevier BV.http://doi.org/10.1016/j.urology.2006.04.034
- Ko, Y., Malone, D. C., & Armstrong, E. P. (2006, December). Pharmacoeconomic Evaluation of Antimuscarinic Agents for the Treatment of Overactive Bladder. Pharmacotherapy. Wiley.http://doi.org/10.1592/phco.26.12.1694